United Laboratories Unit Reports Positive Phase 2 Results for Atopic Dermatitis Drug; Shares Gain 3%

MT Newswires Live11-11

United Laboratories International (HKG:3933) said its wholly owned unit, Zhuhai United Laboratories, has completed a Phase 2 clinical trial in China for TUL01101 tablets, a Class 1 new drug for treating moderate-to-severe atopic dermatitis, according to a Monday bourse filing.

Shares of the firm were up nearly 3% in Tuesday morning trade.

The multicenter trial enrolled 201 adult patients and tested three dose groups over 12 weeks.

All doses showed significant efficacy, with Eczema Area and Severity Index (EASI) score reductions of up to 87.9% and an EASI-75 response rate as high as 84%, according to the filing.

The drug also demonstrated a favorable safety profile, with most adverse events being mild to moderate.

Following the positive results, the company has begun discussions with regulators and is initiating a Phase 3 clinical trial in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582338187?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582338187","market":"sh","top_or_hot":-1,"title":"United Laboratories Unit Reports Positive Phase 2 Results for Atopic Dermatitis Drug; Shares Gain 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ULIHF\">United Laboratories</a> International (HKG:3933) said its wholly owned unit, Zhuhai United Laboratories, has completed a Phase 2 clinical trial in China for TUL01101 tablets, a Class 1 new drug for treating moderate-to-severe atopic dermatitis, according to a Monday bourse filing.</p><p>Shares of the firm were up nearly 3% in Tuesday morning trade.</p><p>The multicenter trial enrolled 201 adult patients and tested three dose groups over 12 weeks.</p><p>All doses showed significant efficacy, with Eczema Area and Severity Index (EASI) score reductions of up to 87.9% and an EASI-75 response rate as high as 84%, according to the filing.</p><p>The drug also demonstrated a favorable safety profile, with most adverse events being mild to moderate.</p><p>Following the positive results, the company has begun discussions with regulators and is initiating a Phase 3 clinical trial in China.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Laboratories Unit Reports Positive Phase 2 Results for Atopic Dermatitis Drug; Shares Gain 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Laboratories Unit Reports Positive Phase 2 Results for Atopic Dermatitis Drug; Shares Gain 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-11 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ULIHF\">United Laboratories</a> International (HKG:3933) said its wholly owned unit, Zhuhai United Laboratories, has completed a Phase 2 clinical trial in China for TUL01101 tablets, a Class 1 new drug for treating moderate-to-severe atopic dermatitis, according to a Monday bourse filing.</p><p>Shares of the firm were up nearly 3% in Tuesday morning trade.</p><p>The multicenter trial enrolled 201 adult patients and tested three dose groups over 12 weeks.</p><p>All doses showed significant efficacy, with Eczema Area and Severity Index (EASI) score reductions of up to 87.9% and an EASI-75 response rate as high as 84%, according to the filing.</p><p>The drug also demonstrated a favorable safety profile, with most adverse events being mild to moderate.</p><p>Following the positive results, the company has begun discussions with regulators and is initiating a Phase 3 clinical trial in China.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2582338187","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582338187","pubTimestamp":1762827460,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"United Laboratories International  said its wholly owned unit, Zhuhai United Laboratories, has completed a Phase 2 clinical trial in China for TUL01101 tablets, a Class 1 new drug for treating moderate-to-severe atopic dermatitis, according to a Monday bourse filing.Shares of the firm were up nearly 3% in Tuesday morning trade.The multicenter trial enrolled 201 adult patients and tested three dose groups over 12 weeks.All doses showed significant efficacy, with Eczema Area and Severity Index  score reductions of up to 87.9% and an EASI-75 response rate as high as 84%, according to the filing.The drug also demonstrated a favorable safety profile, with most adverse events being mild to moderate.Following the positive results, the company has begun discussions with regulators and is initiating a Phase 3 clinical trial in China.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","EASI":"Amplify EASI Tactical Growth ETF","UBCP":"联合合众银行","03933":"联邦制药","BK4211":"区域性银行"},"translate_title":"联邦制药部门报告特应性皮炎药物的积极2期结果；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1,"EASI":1,"UBCP":1.5},"content_text":"United Laboratories International (HKG:3933) said its wholly owned unit, Zhuhai United Laboratories, has completed a Phase 2 clinical trial in China for TUL01101 tablets, a Class 1 new drug for treating moderate-to-severe atopic dermatitis, according to a Monday bourse filing.Shares of the firm were up nearly 3% in Tuesday morning trade.The multicenter trial enrolled 201 adult patients and tested three dose groups over 12 weeks.All doses showed significant efficacy, with Eczema Area and Severity Index (EASI) score reductions of up to 87.9% and an EASI-75 response rate as high as 84%, according to the filing.The drug also demonstrated a favorable safety profile, with most adverse events being mild to moderate.Following the positive results, the company has begun discussions with regulators and is initiating a Phase 3 clinical trial in China.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582338187","isCrawlerRequest":true}